{"prompt": "['IRB Approved', 'Document Release Date: 02/26/2020', 'CC Protocol Number: 9582', 'PI: Michael T. Schweizer, MD', 'Apalutamide in Active Surveillance patients', 'Protocol Version: 6.0; September 06, 2019', '2. Study Objectives', '2.1. Primary Objective', 'Determine the negative repeat biopsy rate by site directed and systematic prostate', 'biopsy after 90-days of apalutamide.', '2.2. Secondary Objectives', '1. Determine the rate of exit at 2 years from active surveillance due to pathologic', 'reclassification', '2. Determine the overall rate of exit at 2 years from active surveillance.', '3. Determine the rate of local treatment (e.g., radical prostatectomy, radiation therapy,', 'brachytherapy) at 2 years and the local treatment free survival.', '4. Determine PSA progression rates and PSA progression free survival (PFS), as', 'defined by the Prostate Cancer Working Group 2 (PCWG2) criteria.\u00b9', '5. Determine the rate of radiographic disappearance of MRI detectable prostate', 'cancer following treatment (only in patients with a baseline nodule that is PIRADS 3', 'or more and >5mm).', '6. Investigate the safety of apalutamide in men undergoing active surveillance.', 'a. Safety will be evaluated by the incidence, severity, duration, causality,', 'seriousness, and type(s) of adverse events as assessed by the revised', 'National Cancer Institute Common Terminology Criteria for Adverse', 'Events (NCI CTCAE), version 4.03 published 14 June 2010.', '7. Track quality of life utilizing the FACT-P and SF36 surveys for each cohort.', '8. Exploratory biomarker Assessment. Examples of these may include, but are not', 'limited to: assessment for genomic PTEN loss via fluorescence in situ hybridization', '(FISH), PTEN immunohistochemistry (IHC), assessment for alteration in', 'MYC/chromosome 8q24 via FISH and tumor mRNA expression profiling/risk', 'classification (e.g., Decipher, Oncotype DX Prostate Cancer Assay, or RNA-seq).', '25', 'Printed on 1/29/2021']['IRB Approved', 'Document Release Date: 02/26/2020', 'CC Protocol Number: 9582', 'PI: Michael T. Schweizer, MD', 'Apalutamide in Active Surveillance patients', 'Protocol Version: 6.0; September 06, 2019', '2.3. Primary Endpoint', 'Negative (i.e., no residual carcinoma) site directed and systematic prostate biopsy', 'following 90-days of apalutamide.', '2.4. Secondary Endpoints', '1. Exit from active surveillance due to pathologic reclassification at 2 years.', '2. Exit from active surveillance for any reason at 2 years.', '3. Local treatment (e.g., radical prostatectomy, radiation therapy, brachytherapy) at 2', 'years and the local treatment free survival.', '4. PSA progression and PSA progression free survival (PFS), as defined by the', 'Prostate Cancer Working Group 2 (PCWG2) criteria [Scher et al, 2008].', '5. Radiographic disappearance of MRI detectable prostate cancer following treatment', '(in patients with a baseline nodule that is PIRADS 3 or more and >5mm).', '6. Safety of apalutamide in men undergoing active surveillance.', 'a. Safety will be evaluated by the incidence, severity, duration, causality,', 'seriousness, and type(s) of adverse events as assessed by the revised', 'National Cancer Institute Common Terminology Criteria for Adverse', 'Events (NCI CTCAE), version 4.03 published 14 June 2010.', '7. Quality of life as assessed using the FACT-P and SF36 surveys.', '8. Exploratory biomarkers assessment. Examples of these may include, but are not', 'limited to: assessment for genomic PTEN loss via fluorescence in situ hybridization', '(FISH), PTEN mmunohistochemistry (IHC), assessment for alteration in', 'MYC/chromosome 8q24 via FISH and tumor mRNA expression profiling/risk', 'classification (e.g. Decipher, Oncotype DX Prostate Cancer Assay, or RNA-seq).', '26', 'Printed on 1/29/2021']\n\n###\n\n", "completion": "END"}